Nalaganje...

Combinatorial immunotherapy with checkpoint blockers solves the problem of metastatic melanoma—An exclamation sign with a question mark

Results from recent clinical trials demonstrate that a combinatorial immunotherapeutic regimen based on 2 distinct checkpoint blockers, namely, the CTLA4-targeting agent ipilimumab and the PD-1-specific molecule nivolumab, causes objective responses in a majority of subjects with advanced melanoma....

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Oncoimmunology
Main Authors: Kroemer, Guido, Galluzzi, Lorenzo
Format: Artigo
Jezik:Inglês
Izdano: Taylor & Francis 2015
Teme:
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4485790/
https://ncbi.nlm.nih.gov/pubmed/26140249
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2015.1058037
Oznake: Označite
Brez oznak, prvi označite!